* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Educational Items Section Apparently balanced structural chromosome rearrangements (ABSCRs) and abnormal phenotype
Nutriepigenomics wikipedia , lookup
Polycomb Group Proteins and Cancer wikipedia , lookup
Dominance (genetics) wikipedia , lookup
Ridge (biology) wikipedia , lookup
Genomic library wikipedia , lookup
Oncogenomics wikipedia , lookup
History of genetic engineering wikipedia , lookup
Skewed X-inactivation wikipedia , lookup
Human genome wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Medical genetics wikipedia , lookup
Genomic imprinting wikipedia , lookup
Non-coding DNA wikipedia , lookup
Y chromosome wikipedia , lookup
Comparative genomic hybridization wikipedia , lookup
Epigenetics of human development wikipedia , lookup
Genome evolution wikipedia , lookup
Minimal genome wikipedia , lookup
Quantitative trait locus wikipedia , lookup
Genome (book) wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Segmental Duplication on the Human Y Chromosome wikipedia , lookup
Microevolution wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Educational Items Section Apparently balanced structural chromosome rearrangements (ABSCRs) and abnormal phenotype Jean Marie Rival Medical genetic service - CHU Nantes, France (JMR) Published in Atlas Database: March 2009 Online updated version: http://AtlasGeneticsOncology.org/Educ/BalancedRearAbnorID30071ES.html DOI: 10.4267/2042/44697 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2010 Atlas of Genetics and Cytogenetics in Oncology and Haematology I. Facts II. Molecular basis of the phenomenon I. Facts molecular cytogenetics techniques, mainly the array CGH (Table 2). - Conversely, patients with a normal phenotype and ABSCRs were found to carry no imbalance. - The majority of de novo imbalances have a paternal chromosome origin. - ABSCRs breakpoints were compared in patients with normal and abnormal phenotype: No significant differences were found in GC contents, nor in the number of CpG islands, the number of genes, exons and genes disrupted, the number of segmental duplications and copy number variants in the 200 Kb window around and within the breakpoints. - Live birth prevalence of ABSCRs is estimated around 0,8%-1%. 15-20 % of which occur de novo, and 80-85 % are inherited. - Most individuals with ABSCRs have a normal phenotype. However, the risk for abnormalities exists. It is relatively low in inherited cases, but high in de novo cases (Table 1). - De novo rearrangements represent a challenge in prenatal diagnosis given that the risk of malformations and learning disabilities is about 5-10%. - In patients with an abnormal phenotype, ABSCRs host “cryptic” chromosomal rearrangements (more often deletions, rarely duplications), uncovered by TABLE 1: Patients with an apparently balanced chromosome rearrangement Risk of an abnormal phenotype* Familial cases ascertained through MR/MCA** 10-15% sterility 3% 50% De novo cases *Risk: proband excluded in familial cases **MR: mental retardation, MCA: major congenital abnormalities Atlas Genet Cytogenet Oncol Haematol. 2010; 14(2) 232 Apparently balanced structural chromosome rearrangements (ABSCRs) and abnormal phenotype Rival JM TABLE 2: Patients with an abnormal phenotype Cryptic imbalance Familial cases 25% De novo cases 33%* *In de novo cases with complex ABSCRs (with more than 3 breakpoints), imbalance was found in 90 % Only the number of breakpoints in G-bands versus Rbands was statistically significant (p < 0.01): patients with one or both breakpoints within R-bands had more often an abnormal phenotype. The proportion of gene disruption (at the breakpoints) was similar in patients with normal and abnormal phenotypes. However, genes implicated in biological processes of the nervous system, genes for transcription/regulation of transcription or signal transduction/signalling, and genes associated with known Mendelian diseases were more frequently disrupted in patients with an abnormal phenotype. was studied. Alternating purine-pyrimidine sequences, polypurine or polypyrimidine tracts were found to be significantly overrepresented in the vicinity of deletions and translocation breakpoints junctions. - Such sequences are prone to form non B-DNA configurations (triplex, tetraplex, cruciform, slipped or Z-DNA).They are detected for example near the breakpoints of the recurrent t(11;22). - These structures are likely to slow down or arrest the replication fork processing. Serial steps of intra and/or inter chromosomal replication slippage can explain complex genome rearrangements. - The initial breakage event involved in many constitutional and somatic translocations is thought to be the result of stalled DNA replications. - A single DNA strand lesion -rather than a double stand break- as the initiating damage that causes replication fork stalling, may be the mechanism involved in this process. II. Molecular basis of the phenomenon - A molecular analysis of 18 breakpoints in patients with an abnormal phenotype revealed 11 microdeletions (deletions of 1 to 16 bp), 6 insertions (217 bp), 2 duplications (3 and 13 bp) and 3 multiples sequences changes. - The oligonucleotide composition of the breakpoints Fig 1: Secundary structure at the breakpoint 8q24.13 in a t(8;22) translocation (from Gotter AL et coll., Genome Res 2007,17(4),470), Cold Spring Harbor Laboratory Press. Atlas Genet Cytogenet Oncol Haematol. 2010; 14(2) 233 Apparently balanced structural chromosome rearrangements (ABSCRs) and abnormal phenotype Fig 2: Numerous loci replicate at a given time, possibly favoring non-B DNA structure formation. This article should be referenced as such: Rival JM. Apparently balanced structural chromosome rearrangements (ABSCRs) and abnormal phenotype. Atlas Genet Cytogenet Oncol Haematol. 2010; 14(2):232-234. Atlas Genet Cytogenet Oncol Haematol. 2010; 14(2) 234 Rival JM